Targeting PKC iota-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma by Ito, Masaoki et al.
RESEARCH Open Access
Targeting PKCι-PAK1 signaling pathways in
EGFR and KRAS mutant adenocarcinoma
and lung squamous cell carcinoma
Masaoki Ito1,2,3, Carles Codony-Servat1,4, Jordi Codony-Servat1, David Lligé2, Imane Chaib2, Xiaoyan Sun5,
Jing Miao5, Rongwei Sun5, Xueting Cai5, Alberto Verlicchi1,8, Morihito Okada3, Miguel Angel Molina-Vila1,
Niki Karachaliou1, Peng Cao5,6,7* and Rafael Rosell2,9,10*
Abstract
Introduction: p21-activated kinase 1 (PAK1) stimulates growth and metastasis in non-small cell lung cancer
(NSCLC). Protein kinase C iota (PKCι) is an enzyme highly expressed in NSCLC, regulating PAK1 signaling. In the
present study we explored whether the PKCι-PAK1 signaling pathway approach can be an efficient target in
different types of NSCLC cell and mouse models.
Methods: The effect of IPA-3 (PAK1 inhibitor) plus auranofin (PKCι inhibitor) combination was evaluated by cell
viability assay, colony formation and western blotting assay, using three types of NSCLC cell lines: EGFR or KRAS
mutant adenocarcinoma and squamous cell carcinoma with PAK1 amplification. In addition, for clinical availability,
screening for new PAK1 inhibitors was carried out and the compound OTSSP167 was evaluated in combination
with auranofin in cell and mice models.
Results: The combination of IPA-3 or OTSSP167 plus auranofin showed high synergism for inhibiting cell viability
and colony formation in three cell lines. Mechanistic characterization revealed that this drug combination
abrogated expression and activation of membrane receptors and downstream signaling proteins crucial in lung
cancer: EGFR, MET, PAK1, PKCι, ERK1/2, AKT, YAP1 and mTOR. A nude mouse xenograft assay demonstrated that
this drug combination strongly suppressed tumor volume compared with single drug treatment.
Conclusions: Combination of IPA-3 or OTSSP167 and auranofin was highly synergistic in EGFR or KRAS mutant
adenocarcinoma and squamous cell carcinoma cell lines and decreased tumor volume in mice models. It is of
interest to further test the targeting of PKCι-PAK1 signaling pathways in EGFR mutant, KRAS mutant and squamous
NSCLC patients.
Background
Non-small cell lung cancer (NSCLC) is the leading
cause of cancer related deaths and comprises several
histological subtypes: lung adenocarcinoma (LUAD),
squamous cell carcinoma (SCC) and large cell carcin-
oma. Despite the identification of targeted druggable
driver mutations and rearrangements, most cases have
poor survival [1, 2]. Recently, pembrolizumab plus
chemotherapy have provided benefit in a fraction of
patients, regardless of the level of PD-L1 expression
[3–5]. However, the effect of immunotherapy in pa-
tients with EGFR mutations is rather limited [6]. A
meta-analysis indicated that immuno-checkpoint in-
hibitors as second line treatment do not improve over-
all survival in comparison with docetaxel treatment in
EGFR-mutant patients [7]. We focus our research on
the identification of recurrent pathways occurring in
subclasses of NSCLC, including LUADs driven by
KRAS or EGFR mutations, and SCC. This stems from
the fact that atypical protein kinase Cι binding to Par6
is associated with the epithelial cell transforming
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sequence 2 (Ect2), a guanine nucleotide exchange fac-
tor that activates Rac1 in downstream PAK1, MEK1/2-
ERK1/2 signaling, regulating tumor growth in NSCLC
[8–10]. PKCι is reported to be amplified in 20.2–36.5%
of NSCLC patients, especially in SCC patients [8, 11].
PKCι mRNA is overexpressed in LUAD and SCC cell
lines and tumor tissue, and is predictive of poor out-
come [12]. The abundance of PKCι mRNA predicted
sensitivity to an anti-rheumatoid agent, aurothioma-
late, in a panel of lung cancer cell lines [8]. Auranofin,
a gold complex used to treat rheumatoid arthritis was
shown to inhibit the PI3K/AKT/mTOR signaling in
NSCLC cell lines. The administration of auranofin to
mice with xenograft tumors significantly suppresses
tumor growth without inducing toxic effects [13]. It is
of interest that auranofin enhances ibrutinib activity in
EGFR mutant LUAD by inhibiting the expression or
phosphorylation of multiple key nodes in AKT/mTOR
and MEK/ERK pathways [14]. Furthermore, it has been
demonstrated that PKCι plays an important function
in KRAS LUADs [15, 16]. PAK1 is a Ste20 (MAP 4 K)
member that is frequently overexpressed or amplified,
and has a critical function in cell growth migration,
invasion and apoptosis in NSCLC [17]. PAK1 confers
cisplatin resistance in NSCLC patients [18]. PAK1 sig-
naling has been shown to cause resistance to MAPK
kinase inhibitors in BRAF mutant melanomas [19].
PAK1 mRNA expressing EGFR mutant tumors are
resistant to EGFR tyrosine kinase inhibitors. The com-
bination of gefitinib with an AKT inhibitor (perifosine)
or PAK1 inhibitor (IPA-3) almost completely sup-
presses the tumor burden in nude mice harboring gefi-
tinib resistant cells [20]. Together with others, we have
demonstrated that the combination of AKT and EGFR
inhibitors could be of benefit in patients with EGFR
mutations [21] [22], however, even when blocking
AKT, tumor regrowth could occur through the activation
of other downstream regulators, via Src/FAK [22, 23]. We
posit that different classes of LUADs, such as EGFR mu-
tant LUADs, KRAS mutant LUADs and SCCs, could be
sensitive to the inhibition of PKCι with auranofin plus a
PAK inhibitor. Several attempts have been made to specif-
ically target PAK1 in cancer, however, its catalytic pocket
is large and highly flexible, in addition to its highly mobile
N-terminal lobe, which presented a challenge in prevent-
ing specific PAK inhibitors [24, 25]. For this reason, we
used IPA-3 (2,2′-dihydroxy-1,1′-dinaphthyldisulfide) as a
PAK inhibitor [26] with PKCι inhibitor.
This study aimed to estimate the therapeutic effect of
PKCι-PAK1 signaling pathways in different types of NSCLC.
Materials and methods
Detail of standard methodologies for cell culture, re-
agents, cell viability assay, colony formation assay, and
western blotting analysis are described in Supplementary
materials and methods.
In vitro screening for PAK1 inhibitor
The measurement of PAK1 kinase was performed on a
Caliper LabChip EZ Reader II equipped with a 12-sipper
chip in Profiler Pro separation buffer supplemented with
CR-8 and analyzed using EZ Reader software (Caliper Life
Sciences; Hopkinton, MA, USA). The test compounds
were incubated with PAK1 kinase and fluorescence-labeled
substrate Peptide 14 (Sequence RRRLSFAEPG) in the kin-
ase assay buffer at 30 °C for 10min, followed by adding
9.5 μM ATP to initiate the reaction. After incubation for 1
h at 30 °C, the phosphorylated and unphosphorylated sub-
strates were separated and detected by EZ Reader II device.
IPA-3 was used as a positive control. The separation of
peptide 14 was performed under the following optimized
conditions: upstream voltage = − 500 V, downstream volt-
age = − 2400 V and pressure = − 1.4 psi using a marker dye
consisting of unphosphorylated peptide 14. After PAK1
inhibitors were screened from the Target Mol-Inhibitory-
Library, the anti-tumor effects of candidates were esti-
mated by MTT assay using A549 cell lines.
Nude mouse xenograft
Four to five-week-old female nude mice were kept in in-
dividually ventilated cages (5 per cage) with access to
food and water, at 20 °C and 50 ± 20% relative humidity
under a 12:12 h light-dark cycles and pathogen free
conditions. Three cell line xenograft tumors were estab-
lished by subcutaneously injecting 4 × 106 cells sus-
pended in phosphate-buffered saline mixed 1:1 with
Corning Matrigel (356,237, Corning, NY, USA) via right
flank. Tumor size was measured in two orthogonal
directions using calipers every 2 days and weights were
determined every 2 days. After tumors became palpable
(~ 100–300 mm3), mice were randomized into a vehicle
group and treated groups with IPA-3 alone, auranofin
alone, OTSSP167 alone, IPA-3 plus auranofin, or
OTSSP167 plus auranofin. Each reagent was suspended
in 1% [weight/volume (w/v)] Kolliphor HS15 and admin-
istered once daily by intraperitoneal administration
(IPA-3 and auranofin) or oral gavage (OTSSP167) of 10
mg/kg. Mice in the untreated group were given the same
volumes of 1% Kolliphor HS15. The tumor volume
(mm3) was estimated using the equation length ×
(width)2 × 0.5.
Statistical analysis
In MTT and colony forming assays, the strength of inter-
action between reagents was determined by calculating
the combination index (CI) according to method of
isobologram-combination index (Chou-Talalay method
[27]). The CI < 0.6, 0.6 < CI < 0.8, 0.8 < CI < 0.9, 0.9 < CI <
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1.1, 1.1 and > 1.1 indicates strong synergism, moderate
synergism, slight synergism, additive interaction, and
antagonism, respectively. In mice xenograft experience,
volume and weight of tumor and mice body weight were
compared as continuous variables by using Mann-
Whitney U tests. Two-sided statistics was employed and a
p value of less than 0.05 was regarded as significant.
Results
The combination of a PAK1 inhibitor plus antitumoral
compounds showed cell viability and colony formation
inhibition synergy
To investigate the potential antitumoral properties and
possible synergistic effect of a PAK inhibitor (IPA-3)
combination with several compounds used in cancer
treatment, such as EGFR inhibitors (osimertinib and
afatinib), PKCι inhibitor (auranofin), MEK inhibitor (tra-
metinib), and a Flk3/Syk, and potential multiple PKC in-
hibitor (midostaurin), several lung cancer cell lines
possessing different molecular characteristics were
tested, such as HCC827 (EGFR mutated), H23 (KRAS
mutated) and H520 (PAK1 overexpression). We evalu-
ated cell viability and colony formation inhibition. Re-
sults indicated that the IPA-3 plus osimertinib
combination showed synergism in H23 cell lines in cell
viability assays with a CI of 0.73. IPA-3 plus trametinib
was also synergistic in the H23 cell line (CI was 0.74)
(Fig. 1a). To highlight, IPA-3 plus PKCι inhibitor, aura-
nofin, showed the highest synergism in each of the 3 cell
lines (CI ranged 0.34 to 0.39) regardless of difference in
histology or genetic profile (Fig. 1). IPA-3 plus midos-
taurin was slightly synergistic or addictive in 3 cell lines.
The CIs of each combination treatment were shown in
Table 1. The IC50s of each inhibitor in 3 cell lines are
shown in Additional file 1: Table S1.
Furthermore, dose-dependent colony formation assays
indicated that the combination of IPA-3 plus auranofin
significantly inhibited the forming of colonies, compared
to single agent treatment and showed high synergism in
3 cell lines (lowest CI ranging from 0.24–0.46) (Fig. 2
and Additional file 1: Figure S1). The values of quantifi-
cation of crystal violet concentration are shown in Fig.
2b and Additional file 1: Figure S1B/S1E. The combin-
ation index value was calculated to assess the nature of
drug-drug interactions and it decreased in a dose-
dependent manner (Fig. 2c and Additional file 1: Figure
S1C/S1F).
The combination of a PAK1 inhibitor plus antitumoral
compounds downregulated the expression of proteins
related to deregulated signaling pathways in lung cancer
To study the mechanisms involved in the synergism be-
tween IPA-3 and auranofin, we analyzed the effects of
this combination in the expression and phosphorylation
Fig. 1 Cell viability and combination index by MTT assay testing single or combination treatment. a-c The effect in cell viability of the
combination of the PAK inhibitor IPA-3 and the PKCι inhibitor auranofin was assessed by MTT assay in HCC827, H23 and H520 cell lines. The
experiments were performed by triplicate. Drug concentration was increased gradually from 0 to 3 times of IC50. Cell viability on combination
treatment (green line) was decreased significantly in comparison to single drug treatment (red and blue line). d-e Range of combination index of
combination treatment on each cell line. Gray part is the area corresponding to addictive interaction. The combination of IPA-3 plus auranofin
was synergic and showed lowest combination index (0.34–0.39) in 3 cell lines. IPA-3 plus midostaurin was synergic only in HCC827 and IPA-3 plus
osimertinib was synergic only in H23
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of proteins that belong to several signaling pathways
related to lung cancer. Cell lysates were harvested after
being treated with the indicated drug concentrations for
6 h and subjected to western blotting analysis. Results
showed that the combination of IPA-3 plus auranofin
abrogated the expression of total/phosphorylation of
PAK1, PKCι, ERK 1/2, mTOR, AKT, and YAP1 in the 3
lung cancer cell lines studied HCC827 (EGFR-mutant
LUAD), H23 (KRAS-mutant LUAD) and H520 (PAK1
overexpression). Also, downregulation of protein expres-
sion of EGFR, MEK, AXL, Src and STAT3 was observed.
(Fig. 2 and Additional file 1: Figure S2). In summary,
there is a clear downregulation of proteins, and, in most
of them, a clear decrease in phosphorylation was de-
tected when combining IPA-3 plus auranofin, indicating
that this drug combination may target multiple signaling
pathways. In addition, we investigated the molecular
effects of auranofin combined with osimertinib, an EGFR
inhibitor used in EGFR-mutated lung cancer patients.
The drug combination was tested in the EGFR-mutated
cell line, HCC827, at the indicated dose for a period of
6 h. Protein lysates were analyzed by western blotting
technique which showed a clear protein expression
decrease in AKT, MET, AXL and CDCP1 (Fig. 2). We
carried out similar experiments with the combination of
auranofin plus trametinib, a MEK inhibitor, in the KRAS
mutated cell line, H23, and observed a clear downregula-
tion of PAK1, PKCι, EGFR, ERK 1/2, AKT, MET, AXL,
STAT3, and MEK 1/2. Inhibition of phosphorylated
PAK1 (Ser144), PKCι, ERK 1/2, STAT3 and MEK 1/2
was also observed.
Screening of alternative PAK1 inhibitor and validation of
combination therapeutic effect with auranofin
To identify pharmacological inhibitors of PAK1 kinase
activity, we screened the Target-Mol inhibitor library
based on an optimized LabChip EZ Reader kinase assay
system. Titration and validation of the kinase assay are
shown in Additional file 1: Figure S3. Out of 320 com-
pounds tested, 13 candidates showed PAK1 inhibitory ef-
fect. The details and inhibition ratio of each compound are
shown in Additional file 1: Table S2 and Additional file 1:
Figure S4. Among them, the PAK1 inhibitory effects of
some compounds, such as bosutinib (1-A5), WH-4-023 (3-
F9), and MHY1485 (4-H9), were comparable to IPA-3, and
their inhibitory effect on cell growth was estimated
using the MTT assay. Cell viability tested in A549 cell
lines showed that 5 compounds (bosutinib, thonzo-
nium bromide, AT13148, OTSSP167, and reversine)
significantly suppressed cell growth at the concentra-
tions of 10 and 20 μM (Fig. 3).
Furthermore, among 5 potential PAK1 inhibitors,
OTSSP167 plus auranofin showed synergism in 3 cell
lines. CIs in MTT assay were 0.78–0.79. The protein
expressions of phosphorylated PAK1 were suppressed by
× 0.5, × 1.0, and × 3.0 times higher dose of IC50 (Fig. 4).
Reversine indicated synergism with auranofin only in
H520 cell lines (CI: 0.76). The IC50 and CI of OTSSP167
or reversine plus auranofin are shown in Table 2. Colony
formation assay showed synergistic effect of OTSSP167
plus auranofin in 3 cell lines with lowest CI ranging from
0.50–0.59 (Fig. 5a-c and Additional file 1: Figure S5).
Western blotting experiments showed that OTSSP167
inhibited more PAK1 phosphorylated residues compared
to IPA-3. The combination of OTSSP167 plus auranofin
abrogated phosphorylated PAK1 (Thr432 and Ser144 in 3
cell lines) (Fig. 5d). In addition, the combination of these
two drugs downregulated the PKCι expression and inhib-
ited its phosphorylation.
The combination of PAK1 and PKCι inhibitors suppressed
tumorigenesis in a nude mouse Xenograft model
We performed nude mice xenograft experiments to explore
the pharmacological combined effect of PAK1 and PKCι
inhibitors. HCC827, H23, or H520 cell lines were inocu-
lated subcutaneously into mice and when tumor size
reached an average volume of 100–300mm3, single reagent
(IPA-3, OTSSP167, auranofin) or combination of IPA-3 or
OTSSP167 plus auranofin or vehicle were inoculated via
intraperitoneal administration (auranofin and IPA-3) or
oral gavage (OTSSP167) every 2 days for 2 or 4 weeks.
Combination therapy showed stronger anti-tumor effect
compared to mono therapy in 3 mice model cell lines. IPA-
3 plus auranofin inhibited tumor growth, both in volume
and weight, compared to IPA-3 alone or auranofin alone.
The combination of OTSSP167 plus auranofin showed
significant inhibition of tumor growth in the 3 mice model
cell lines compared to single OTSSP167 or auranofin treat-
ment (Fig. 6 and Additional file 1: Figure S6). Compared to
vehicle group, mice body weight was significantly reduced
in OTSSP167 plus auranofin and single OTSSP167 treat-
ment in the 3 mice model cell lines. The combination of
IPA-3 plus auranofin induced significant body weight loss
in HCC827 and H520 cell lines mice models.
Discussion
Inactive PAK1 is reported to be a homodimeric pro-
tein. Binding of Cdc42/Rac1 to Cdc42/Rac1-binding



















HCC827 0.951 0.876 0.371 0.819 1.123
H23 0.944 0.727 0.376 0.902 0.836 0.929
H520 0.838 0.794 0.347 1.073 0.766
Abbreviations: Afa afatinib, Aura auranofin, Mido midostaurin, Osi osimertinib,
Tra trametinib
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domain (CRIB) relieves inhibition by disrupting the
PAK1 homodimer [28]. PAK1 is activated by several
mechanisms that include PKCι commonly upregulated
in NSCLC [12, 29], such as TNFα, CD3/CD28 (T cell
receptor engagement). EGFR signaling actively
suppresses TNF mRNA levels by inducing expression
of miR-21. EGFR TKIs result in loss of miR-21 and in-
crease TNF mRNA stability, leading to EGFR TKI
resistance in EGFR mutant NSCLC [30]. Therefore, it
is tempting to speculate that an EGFR TKI, PAK
Fig. 2 Cell viability by colony forming assay and western blotting by treatment using single reagent or combination of IPA-3 plus auranofin in
HCC827 cell lines. IPA-3 plus auranofin potentiates colony formation inhibition and protein expression. a HCC827 cell colonies were grown under
single or combination increasing dose of IPA-3 and/or auranofin. Fixed colonies were stained using crystal violet. The experiments were made at
least three times and a representative image of colon formation assay is shown. b Concentration of crystal violet was represented as ratio to
control (non-treatment colonies defined as 1). Crystal violet was absorbed using 2% sodium dodecyl sulfate and measured at 570 nm. c
Combination index by each concentration of IPA-3 and auranofin. Combination index decreased in dose-dependent manner. Combination index
was included in synergistic area (< 0.9). d HCC827 cell line was exposed to 50 μM IPA-3, 15 μM auranofin or 0.1 μM osimertinib and the
combinations of IPA-3 plus auranofin or osimertinib for 6 h. Protein expression and activation were analyzed by western blotting. Actin was used
as house-keeping protein. The experiments were made at least twice. Abbreviations: S, serine; T, threonine; Y, tyrosine
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inhibitor combination could serve as novel combin-
atory therapy for EGFR mutant NSCLC. The develop-
ment of PAK1 inhibitors is difficult due to their large
and highly flexible catalytic pocket and highly mobile
N-terminal lobe [29, 31, 32]. PAK inhibitor combina-
tions with targeted drugs have been tested in NSCLC
cell lines, including apoptosis protein inhibitors (IAP,
EGFR, MEK1/2 and Src inhibitors with PAK1 knock-
down) [33]. Strong combinatorial activity was con-
firmed for dual inhibition of PAK1 and IAP in EBC-1
cells [33]. Activity was demonstrated with an inhibitor
targeting PAK1 activation-3′ (IPA-3) [33]. However,
the cardiac toxicity noted with IPA-3 prevents its clin-
ical use [34]. PAK1 serves as a mediator of intracellular
calcium ion homeostasis in the heart. PAK1 inhibition
induces exaggeration of calcium ion and arrhythmia
[35, 36]. Although it is unknown whether the toxicity
is reversible or not, the risk can be reduced by lower doses
of IPA-3 [34]. An auranofin phase I study for rheumatoid
arthritis patients [37] and a randomized multicenter study
for asthma patients [38] have reported no cardiac toxicity.
Our study suggested that the dose of IPA-3 can be
decreased in combination with auranofin. Nevertheless,
cardiac toxicity is a major concern and attention should
be paid to safety use in PKCι-PAK1 signaling strategy. We
tested the combination of IPA-3 plus other inhibitors in
cell models. IPA-3 plus auranofin showed high synergism
in cell viability and colony formation assays in three
NSCLC cell lines used. The inhibitory effect was superior
to other combinations, such as EGFR tyrosine kinase in-
hibitors (either osimertinib or afatinib) in the HCC827, or
MEK inhibitor (trametinib) in the H23 cell line. Also, in
the SCC cell line, the combination index was significant
for IPA-3 plus auranofin. Auranofin has already been clin-
ically available for rheumatoid arthritis and a clinical trial
for NSCLC and small cell lung cancer is ongoing
(NCT01737502). Another PKCι inhibitor, gold compound
aurothiomalate, is also clinically available for rheumatoid
arthritis and a phase I study has been successfully per-
formed for advanced NSCLC [39]. However, IPA-3 has
never been clinically used so we explored a PAK1 inhibi-
tor with potential clinical availability.
OTSSP167 is a maternal embryonic leucine-zipper kinase
(MELK) inhibitor with anti-cancer effect reported in several
tumors, as well as in chronic lymphocytic leukemia [40].
The anti-tumor effects of OTSSP167 have been investigated
in breast cancer (NCT02926690) and leukemia (NCT0279
5520) clinical trials [40–42]. OTSSP167 [41] inhibited
Fig. 3 Structures and cell growth inhibitions of the selected PAK1 inhibitors tested in A549 cell lines based on the preliminary screening
(Additional file 1: Figure S4). The effect in cell viability of the potential PAK inhibitors. A549 cells were incubated with the 9 compounds at the
concentration of 10 or 20 μM for 72 h and the cell viability was determined using MTT assay. Five compounds (1-A5, 1-C10, 2-C11, 3-A7, and 3-
H3) significantly suppressed the growth of A549 cell lines at the range concentration of 10 and 20 μM. Statistical analysis was performed by
comparing with the value of control. The experiments were made by triplicate. a-e The structures of 5 compounds which suppressed the cell
viability. f Cell inhibition ratio on tested 9 compounds. Five compounds surrounded red square showed high PAK1 inhibition
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PAK1 with lower IC50 than other potential PAK1 inhibi-
tors, such as bosutinib [43], thonzonium bromide [44],
AT13148 [45] and reversine [46] (Fig. 4) and showed high
synergism with auranofin in all three cell lines.
The phosphorylated residue Ser144 of PAK1 was inhib-
ited in three cell lines. The phosphosites, Ser21 or Thr423,
also contribute towards PAK1 activation, although, Ser144
is the most critical for PAK kinase activity [47]. Phosphor-
ylated Ser144 on PAK1 was abrogated by IPA-3 plus aura-
nofin, as well as by OTSSP167 plus auranofin.
Our model showed that some PAK1 phosphosites
were inhibited by, not only IPA-3, but also auranofin
alone. IPA-3 did not inhibit PKCι expression. This sug-
gests that auranofin inhibits PAK1 from the upper
stream of PKCι-PAK1 signaling and stronger inhibition
of PKCι-PAK1 signaling resulted in stronger
synergism. Although osimertinib monotherapy in
HCC827 cell lines or trametinib monotherapy in H23 cell
lines also inhibited some phosphorylated PAK1, the com-
bination of auranofin plus these reagents was not synergis-
tic and showed less abrogation of RTK and non-RTK. In
addition, midostaurin, a FLT3 inhibitor, and a potential in-
hibitor of all PKC isoforms [48] was not synergistic with
auranofin (Fig. 1). In addition, although OTSSP167 served
as a MELK inhibitor, inhibition of MELK expression was
similar between OTSSP167 alone, and OTSSP167 plus
auranofin (Fig. 5d), suggesting that synergism in
OTSSP167 plus auranofin was not induced by MELK in-
hibition. Thus, PKCι-PAK1 signaling is an important path-
way in tumor genesis in EGFR mutant, KRAS mutant and
SCC cell lines. Additionally, due to the inhibition of most
proteins analyzed by the auranofin plus IPA-3 or
OTSSP167 combination, we hypothesize that this com-
pound combination could affect the proteasome activity as
previously reported [49].
In the mice xenograft model, a significant decrease in
tumor volume was confirmed by the OTSSP167 plus
auranofin combination. Although IPA-3 plus auranofin
showed anti-tumor effect, it did not reach a significant
difference. OTSSP167 suggested stronger PAK1 inhib-
ition compared to IPA-3 in western blotting; phosphory-
lated PAK1 at Thr423/Ser144/Thr204 in HCC827 cell
Table 2 IC50 (nM) or combination index (CI) of each single
treatment or combination treatment in 3 cell lines
Reagent HCC827 H23 H520
IC50
OTSSP167 22 18 13
Reversine 350 1300 5300
CI
OTSSP167 + Aura 0.777 0.795 0.783
Reversine + Aura 1.063 1.130 0.795
Abbreviations: Aura auranofin
Fig. 4 Cell viability assay using potential PAK inhibitors. The potential PAK inhibitor OTSSP167 synergizes with auranofin in cell viability
assays. a-c The results of MTT assay using alternative PAK1 inhibitors candidates in 3 cell lines: HCC827 (a), H23 (b), and H520 (c). OTSSP167
showed the lowest IC50 in 3 cell lines (blue line). (d) Combination index of OTSSP167 plus auranofin indicated synergism in 3 cell lines. The
combination of reversine plus auranofin also indicated synergism in H520 cell lines but not in HCC827 and H23 cell lines. (e) OTSSP167
inhibited 3 phosphorylated PAK1 residues at the concentration of 0.5, 1.0, and 3.0 times higher of IC50
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lines and Thr423 in H23 cell lines were inhibited by
OTSSP167 alone, but not by IPA-3 alone. These differ-
ences between IPA-3 and OTSSP167 might explain the
difference in results of the mice xenograft model. Al-
though mice body weight was significantly decreased in
OTSSP167 alone, or OTSSP167 plus auranofin in all 3
cell lines, there was no significant difference between
OTSSP167 alone, and OTSSP167 plus auranofin. Chung
et al. showed OTSSP167 was tolerable in the mice model
without adverse body weight loss [41]. Adverse events of
OTSSP167 should be further examined.
Our research has centered on targeting PKCι-PAK1 sig-
naling and was effective with auranofin plus OTSSP167 in
3 lung cancer models in vitro and in vivo. Although
Fig. 5 Colony formation assay in HCC827 cell lines and western blotting in 3 cell lines by mono therapy or combination treatment of OTSSP167
plus auranofin. The combination of OTSSP167 and auranofin potentiates colony formation inhibition in HCC827 cell lines. Combination of
OTSSP167 and auranofin downregulates expression and inhibits activation of PAK1 and PKCι. a HCC827 cell colonies were grown under single or
combination treatment (OTSSP167 and auranofin) at indicated dose. Fixed colonies were stained using crystal violet. b Concentration of crystal
violet was represented as ratio to control (non-treatment colonies defined as 1). Crystal violet was absorbed using 2% sodium dodecyl sulfate and
measured at 570 nm. c Combination index by each concentration of OTSSP167 and auranofin. Combination index decreased in dose-dependent
manner. Combination index was included in synergistic area (< 0.9). d HCC827, H23 and H520 cell lines were exposed to 3 or 10 μM auranofin
(10 μM for HCC827, 3 μM for H23 and H520) or 1 μM OTSSP167 and the combination of OTSSP167 plus auranofin for 6 h. Protein expression and
activation were analyzed by western blotting. Actin was used as house-keeping protein. The experiments were made at least twice. The
combination of OTSSP167 plus auranofin abrogated the expression and phosphorylation of PAK1 and PKCι. Abbreviations: S, serine; T, threonine;
Y, tyrosine
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Fig. 6 (See legend on next page.)
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OTSSP167 inhibited phosphorylated PAK1, we cannot
rule out that other activators of PAK1 can intervene in
lung cancer, like MLK3 and TNFα.
Auranofin has been investigated in a clinical trial for
NSCLC and small cell lung cancer (NCT01737502). A Phase
I study of OTSSP167 for solid tumors (NCT01910545) and
a feasibility evaluation for healthy volunteers (NCT027685
19) have been completed. Other clinical trials of OTSSP167
are ongoing in breast cancer (NCT02926690) and leukemia
(NCT02795520). Targeting PKCι-PAK1 signaling pathways
is of interest to be further tested clinically in EGFR mutant,
KRASmutant, and squamous NSCLC patients.
Conclusions
The Combination of PKCι-PAK1 inhibitors was highly
synergistic in EGFR and KRAS mutant adenocarcinoma
and squamous cell carcinoma of the lung, in both in vitro
and in vivo mice models. It is warranted to further test the
therapeutic strategy of targeting PKCι-PAK1 signaling
pathways in EGFR mutant, KRAS mutant and squamous
NSCLC patients.
Additional file
Additional file 1: Table S1. Profiles of cell lines and IC50 (nM) of each
reagent. Table S2. The profiles of tested potential PAK1 inhibitors. Figure S1.
IPA-3 and auranofin potentiates colony formation inhibition in H23 and H520
cell lines. Figure S2. Western blotting by treatment using single reagent or
combination of IPA-3 plus auranofin in H23 and H520 cell lines. Figure S3.
Optimization and validation of the kinase assay for PAK1 inhibitor screening.
Figure S4. Summary of cell growth inhibition using potential PAK1 inhibitors.
Figure S5. OTSSP167 plus auranofin potentiates colony formation inhibition
in H23 and H520 cell lines. Figure S6. Anti-tumor effects of single reagent or
combination treatment using IPA-3, auranofin, and OTSSP167 in nude




MI, IC, NK, PC, RR designed the study. MI, CCS, XS, JM, RS, XC, AV performed
the experiments. MI, CCS, JCS, XC, MMV, NK, PC performed the statistics. MI,
CCS, JCS, DL, IC, XC, MMV, NK, PC, RR interpreted the results. ALL authors
read and approved the final manuscript.
Funding
This study was financially supported by International Association for the
Study of Lung Cancer (IASLC) fellowship award. This study was partially
supported by the Major National Science and Technology Program of China
for Innovative Drug (2017ZX09101002–002-006), Key R&D Program of Jiangsu
Province (BE2018755), the Priority Academic Program Development of
Jiangsu Higher Education Institutions (Integration of Chinese and Western
Medicine) grant and Asociación Española Contra el Cáncer (AECC)
PROYE18012ROSE.
Availability of data and materials
Data is shown properly in main manuscript and supplemental files. No
additional data is provided through the special link.
Ethics approval and consent to participate
This study has been approved according World Medical Association
Declaration of Helsinki and institutional ethical guidelines for the research




The authors declare that they have no competing interests.
Author details
1Pangaea Oncology, Laboratory of Molecular Biology, Quiron-Dexeus
University Institute, Barcelona, Spain. 2Laboratory of Cellular and Molecular
Biology, Institute for Health Science Research Germans Trias i Pujol (IGTP),
Badalona, Spain. 3Department of Surgical Oncology, Research Institute for
Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
4IDIBELL/CReST/Translational Research Laboratori L’Hospitalet de Llobregat,
Barcelona, Spain. 5Hospital of Integrated Traditional Chinese and Western
Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
6Laboratory of Cellular and Molecular Biology, Jiangsu Province Academy of
Traditional Chinese Medicine, Nanjing, China. 7Collaborative Innovation
Center for Cancer Medicine, Nanjing Medical University, Nanjing, China.
8Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)
IRCCS, Meldola, Italy. 9Institute of Oncology Rosell (IOR), Quiron-Dexeus
University Institute, Barcelona, Spain. 10Institut d’Investigació en Ciències de
la Salut Germans Trias i Pujol Campus Can Ruti (Edifici Muntanya), Ctra. de
Can Ruti, Cami de les Escoles s/n, Badalona, 08916 Barcelona, Spain.
Received: 31 July 2019 Accepted: 24 September 2019
References
1. Govindan R, Ding L, Griffith M, et al. Genomic landscape of non-small cell
lung cancer in smokers and never-smokers. Cell. 2012;150(6):1121–34.
2. Rosell R, Bivona TG, Karachaliou N. Genetics and biomarkers in
personalisation of lung cancer treatment. Lancet. 2013;382(9893):720–31.
3. Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for
squamous non-small-cell lung Cancer. N Engl J Med. 2018;379(21):2040–51.
4. Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus
chemotherapy in metastatic non-small-cell lung Cancer. N Engl J Med. 2018;
378(22):2078–92.
5. Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for
previously untreated, PD-L1-expressing, locally advanced or metastatic non-
small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled,
phase 3 trial. Lancet. 2019;393(10183):1819–30.
6. Reck M, Mok TSK, Nishio M, et al. Atezolizumab plus bevacizumab and
chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup
(See figure on previous page.)
Fig. 6 Anti-tumor effects of single reagent or combination treatment using IPA-3, auranofin, and OTSSP167 in nude xenograft model in HCC827.
a HCC827 cell lines were used for the xenograft model. Mice were treated once daily with the PAK1 inhibitor (IPA-3 or OTSSP167) single agent or
combined with auranofin at given concentrations. Representative images of tumors measured at the end of the study compared with the control
group are shown. b Line graphs of tumor volumes after treatment by each therapeutic course (vehicle, single reagent, or combination). Tumor
volumes were recorded every 2 days until 14th or 26th day. Errors bars mean + − SD of 5 animals per group. P values by comparing tumor
volumes are described in the table. c Histographs of tumor weight treated by each therapeutic course (vehicle, single reagent, or combination) at
the time of sacrifice. P values by comparing tumor weight are described in the table. d Line graphs of mice weight on every 2 days of each
treatment course (vehicle, single reagent, or combination). P values by comparing mice body weight are described in the table.
Ito et al. Cell Communication and Signaling          (2019) 17:137 Page 10 of 11
analyses of patients with EGFR mutations or baseline liver metastases in a
randomised, open-label phase 3 trial. Lancet Respir Med. 2019;7(5):387–401.
7. Lee CK, Man J, Lord S, et al. Checkpoint inhibitors in metastatic EGFR-
mutated non-small cell lung Cancer-a meta-analysis. J Thorac Oncol. 2017;
12(2):403–7.
8. Regala RP, Weems C, Jamieson L, et al. Atypical protein kinase C iota is an
oncogene in human non-small cell lung cancer. Cancer Res. 2005;65(19):
8905–11.
9. Justilien V, Fields AP. Ect2 links the PKCiota-Par6alpha complex to Rac1
activation and cellular transformation. Oncogene. 2009;28(41):3597–607.
10. Halaoui R, McCaffrey L. Rewiring cell polarity signaling in cancer. Oncogene.
2015;34(8):939–50.
11. Luo Q, Tang L, Lin H, et al. The oncogenic role of PKCiota gene
amplification and overexpression in Chinese non-small cell lung cancer.
Lung Cancer. 2014;84(2):190–5.
12. Regala RP, Thompson EA, Fields AP. Atypical protein kinase C iota
expression and aurothiomalate sensitivity in human lung cancer cells.
Cancer Res. 2008;68(14):5888–95.
13. Li H, Hu J, Wu S, et al. Auranofin-mediated inhibition of PI3K/AKT/mTOR axis
and anticancer activity in non-small cell lung cancer cells. Oncotarget. 2016;
7(3):3548–58.
14. Hu J, Zhang H, Cao M, et al. Auranofin enhances Ibrutinib's anticancer activity
in EGFR-mutant lung adenocarcinoma. Mol Cancer Ther. 2018;17(10):2156–63.
15. Ali SA, Justilien V, Jamieson L, et al. Protein kinase Ciota drives a NOTCH3-
dependent stem-like phenotype in mutant KRAS lung adenocarcinoma.
Cancer Cell. 2016;29(3):367–78.
16. Justilien V, Ali SA, Jamieson L, et al. Ect2-dependent rRNA synthesis is
required for KRAS-TRP53-driven lung adenocarcinoma. Cancer Cell. 2017;
31(2):256–69.
17. Yang Z, Wang H, Xia L, et al. Overexpression of PAK1 correlates with
aberrant expression of EMT markers and poor prognosis in non-small cell
lung Cancer. J Cancer. 2017;8(8):1484–91.
18. Chen MJ, Wu DW, Wang YC, et al. PAK1 confers chemoresistance and poor
outcome in non-small cell lung cancer via beta-catenin-mediated stemness.
Sci Rep. 2016;6:34933.
19. Lu H, Liu S, Zhang G, et al. PAK signalling drives acquired drug resistance to
MAPK inhibitors in BRAF-mutant melanomas. Nature. 2017;550(7674):133–6.
20. Wu DW, Wu TC, Chen CY, et al. PAK1 is a novel therapeutic target in
tyrosine kinase inhibitor-resistant lung adenocarcinoma activated by the
PI3K/AKT signaling regardless of EGFR mutation. Clin Cancer Res. 2016;
22(21):5370–82.
21. Jacobsen K, Bertran-Alamillo J, Molina MA, et al. Convergent Akt activation
drives acquired EGFR inhibitor resistance in lung cancer. Nat Commun.
2017;8(1):410.
22. Ichihara E, Westover D, Meador CB, et al. SFK/FAK signaling attenuates
Osimertinib efficacy in both drug-sensitive and drug-resistant models of
EGFR-mutant lung Cancer. Cancer Res. 2017;77(11):2990–3000.
23. Karachaliou N, Chaib I, Cardona AF, et al. Common co-activation of AXL and
CDCP1 in EGFR-mutation-positive non-smallcell lung Cancer associated with
poor prognosis. EBioMedicine. 2018;29:112–27.
24. Lei M, Lu W, Meng W, et al. Structure of PAK1 in an autoinhibited
conformation reveals a multistage activation switch. Cell. 2000;102(3):
387–97.
25. Jha RK, Strauss CE. 3D structure analysis of PAKs: a clue to the rational
design for affinity reagents and blockers. Cell Logist. 2012;2(2):69–77.
26. Wong LL, Lam IP, Wong TY, et al. IPA-3 inhibits the growth of liver cancer cells
by suppressing PAK1 and NF-kappaB activation. PLoS One. 2013;8(7):e68843.
27. Chou TC. Drug combination studies and their synergy quantification using
the Chou-Talalay method. Cancer Res. 2010;70(2):440–6.
28. Parrini MC, Camonis J, Matsuda M, et al. Dissecting activation of the PAK1
kinase at protrusions in living cells. J Biol Chem. 2009;284(36):24133–43.
29. Lazzari C, Verlicchi A, Gkountakos A, et al. Molecular bases for combinatorial
treatment strategies in patients with KRAS mutant lung adenocarcinoma
and squamous cell lung carcinoma. Pulmonary Therapy. 2016;2(1):1–18.
30. Gong K, Guo G, Gerber DE, et al. TNF-driven adaptive response
mediates resistance to EGFR inhibition in lung cancer. J Clin Invest.
2018;128(6):2500–18.
31. Prudnikova TY, Villamar-Cruz O, Rawat SJ, et al. Effects of p21-activated
kinase 1 inhibition on 11q13-amplified ovarian cancer cells. Oncogene.
2016;35(17):2178–85.
32. Maruta H, Ahn MR. From bench (laboratory) to bed (hospital/home): how to
explore effective natural and synthetic PAK1-blockers/longevity-promoters
for cancer therapy. Eur J Med Chem. 2017;142:229–43.
33. Ong CC, Jubb AM, Haverty PM, et al. Targeting p21-activated kinase 1
(PAK1) to induce apoptosis of tumor cells. Proc Natl Acad Sci U S A. 2011;
108(17):7177–82.
34. Jagadeeshan S, Sagayaraj RV, Paneerselvan N, et al. Toxicity and anti-
angiogenicity evaluation of Pak1 inhibitor IPA-3 using zebrafish embryo
model. Cell Biol Toxicol. 2017;33(1):41–56.
35. Wang Y, Wang S, Lei M, et al. The p21-activated kinase 1 (Pak1) signalling
pathway in cardiac disease: from mechanistic study to therapeutic
exploration. Br J Pharmacol. 2018;175(8):1362–74.
36. DeSantiago J, Bare DJ, Varma D, et al. Loss of p21-activated kinase 1 (Pak1)
promotes atrial arrhythmic activity. Heart Rhythm. 2018;15(8):1233–41.
37. Capparelli EV, Bricker-Ford R, Rogers MJ, et al. Phase I Clinical Trial
Results of Auranofin, a Novel Antiparasitic Agent. Antimicrob Agents
Chemother. 2016;61(1).
38. Bernstein ILBD, Dubb JW, Faiferman I, Wallin B. A placebo-controlled
multicenter study of auranofin in the treatment of patients with
corticosteroid-dependent asthma. J Allergy Clin Immunol. 1996;98(2):317–24.
39. Mansfield AS, Fields AP, Jatoi A, et al. Phase I dose escalation study of
the PKCiota inhibitor aurothiomalate for advanced non-small-cell lung
cancer, ovarian cancer, and pancreatic cancer. Anti-Cancer Drugs. 2013;
24(10):1079–83.
40. Zhang Y, Zhou X, Li Y, et al. Inhibition of maternal embryonic leucine zipper
kinase with OTSSP167 displays potent anti-leukemic effects in chronic
lymphocytic leukemia. Oncogene. 2018;37(41):5520–33.
41. Chung S, Suzuki H, Miyamoto T, et al. Development of an orally-
administrative MELK-targeting inhibitor that suppresses the growth of
various types of human cancer. Oncotarget. 2012;3(12):1629–40.
42. Muller J, Bolomsky A, Dubois S, et al. Maternal embryonic leucine zipper
kinase inhibitor OTSSP167 has preclinical activity in multiple myeloma bone
disease. Haematologica. 2018;103(8):1359–68.
43. Kong JH, Khoury HJ, Kim AS, et al. The safety of Bosutinib for the treatment
of chronic myeloid leukemia. Expert Opin Drug Saf. 2017;16(10):1203–9.
44. Zhu X, Gao JJ, Landao-Bassonga E, et al. Thonzonium bromide inhibits
RANKL-induced osteoclast formation and bone resorption in vitro and
prevents LPS-induced bone loss in vivo. Biochem Pharmacol. 2016;104:
118–30.
45. Yap TA, Walton MI, Grimshaw KM, et al. AT13148 is a novel, oral multi-AGC
kinase inhibitor with potent pharmacodynamic and antitumor activity. Clin
Cancer Res. 2012;18(14):3912–23.
46. Lu YC, Lee YR, Liao JD, et al. Reversine induced multinucleated cells, cell
apoptosis and autophagy in human non-small cell lung Cancer cells. PLoS
One. 2016;11(7):e0158587.
47. Zhou GL, Zhuo Y, King CC, et al. Akt phosphorylation of serine 21 on
Pak1 modulates Nck binding and cell migration. Mol Cell Biol. 2003;
23(22):8058–69.
48. Isakov N. Protein kinase C (PKC) isoforms in cancer, tumor promotion and
tumor suppression. Semin Cancer Biol. 2018;48:36–52.
49. Zhang X, Selvaraju K, Saei AA, et al. Repurposing of auranofin: Thioredoxin
reductase remains a primary target of the drug. Biochimie. 2019;162:46–54.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Ito et al. Cell Communication and Signaling          (2019) 17:137 Page 11 of 11
